PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics, Inc. director Jessica Caroline Chutter filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. The filing does not list any stock transactions or holdings details in the provided data, and serves as a baseline disclosure of her insider status.
PTC Therapeutics has appointed veteran biotechnology investment banker Jessica Chutter to its board of directors, effective March 24, 2026, filling a vacancy. She will serve as a Class I director with a term ending at the 2026 annual meeting of stockholders.
Chutter recently retired from Morgan Stanley after more than 40 years in healthcare investment banking and has advised on about $80 billion of capital raising and $85 billion of strategic transactions. As compensation, she will receive a $50,000 annual cash retainer plus initial and pro-rated 2026 equity grants totaling 6,371 stock options and 7,333 restricted stock units, vesting over multi-year schedules.
PTC Therapeutics CEO Matthew B. Klein reported routine equity compensation activity and a related tax sale. He acquired 12,500 shares of common stock through earned restricted stock units tied to performance-based awards granted in December 2024. The company’s compensation committee certified achievement of a pre-established milestone as of March 11, 2026, causing these units to be earned.
Of the earned units, 6,500 shares vested immediately on March 11, 2026, with the remaining 6,500 scheduled to vest on March 11, 2027. On March 12, 2026, 2,662 shares were automatically sold at $64.08 per share under a pre-set “sell to cover” election to satisfy tax withholding obligations. Following these transactions, Klein directly holds 396,920 shares of PTC Therapeutics common stock.
PTC Therapeutics director Stephanie Okey exercised stock options and sold shares in a pre-planned transaction. On March 10, 2026, she exercised options to acquire 15,167 shares of common stock at an exercise price of $33.63 per share.
On the same date, she sold 15,167 common shares in open-market transactions at a sale price of $70.00 per share pursuant to a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, she holds 8,000 shares of PTC Therapeutics common stock directly.
Matthew Klein reported proposed and recent sales of Common Stock. The filing lists a proposed sale of 2,662 shares on 03/11/2026 tied to restricted stock vesting. The filing also records multiple sales in the prior three months, including 8,089 shares on 12/30/2025 and 7,371 shares on 02/18/2026, with dollar amounts shown for each trade.
Form 144 filing reports proposed and recent sales of common stock. The notice lists 15,167 shares of Common Stock associated with Fidelity Brokerage Services LLC with an entry dated 03/10/2026. The filing also records that Stephanie Okey sold 6,333 shares on 03/05/2026 for $401,385.54.
PTC Therapeutics, Inc. director Stephanie Okey sold 6,333 shares of common stock in an open-market transaction on March 5, 2026 at $63.38 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. After this transaction, she directly holds 8,000 PTC Therapeutics shares.
PTC Therapeutics executive Lee Scott Golden reported an open-market stock sale. On March 5, 2026, the company’s EVP & Chief Medical Officer sold 10,000 shares of PTC Therapeutics common stock at a price of $63.38 per share.
The sale was executed under a written Rule 10b5-1 trading plan that Golden adopted on December 4, 2025. After this transaction, Golden directly owns 79,944 shares of PTC Therapeutics common stock.
PTC THERAPEUTICS, INC. executive Neil Gregory Almstead, the Chief Technical Operations Officer, reported an indirect open-market sale of common stock by his spouse. On March 5, 2026, his spouse sold 3,989 shares of common stock at $63.38 per share in a sale classified as an open-market or private transaction.
This transaction was carried out under a written Rule 10b5-1 trading plan adopted by Almstead on November 26, 2025. Following the sale, his spouse held 2,737 shares of common stock indirectly, while Almstead held an additional 112,140 shares of common stock directly.
Fidelity Brokerage Services LLC filed a Form 144 proposing the sale of Common shares of PTCT. The notice lists restricted stock vesting events on 06/18/2024 (1,334 shares), 02/18/2025 (1,333 shares), 02/19/2025 (1,333 shares) and 01/03/2026 (2,333 shares). The filing identifies the sales agent and class of securities.